Marc Benioff sells and buys Salesforce shares at varying prices on Sept 22.
ByAinvest
Tuesday, Sep 23, 2025 4:23 pm ET1min read
CRM--
Salesforce, Inc. [CRM] has announced that Director, Chairman and CEO Marc Benioff has engaged in various transactions on September 22, 2025. Specifically, he sold 251 shares at $245.08 per share and purchased 2,250 shares at $161.50 per share. Additionally, he sold a total of 1,969 shares at prices ranging from $249.37 to $250.10 per share. These transactions demonstrate the active involvement of Mr. Benioff in the company's share dealings.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet